^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug: | Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Observational clinical study of anlotinib hydrochloride combined with gefitinib in first-line treatment of EGFR-sensitive mutations in advanced NSCLC
Excerpt:
......
Trial ID:
Source:
Title:
Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save Study
Excerpt:
...- No-drive gene mutaion (EGFR、ALK、ROS1） by NGS...
Trial ID:
More C2 evidence
Source:
Title:
Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib
Excerpt:
...- Histologically confirmed that EGFR sensitive mutation (ex19del or L858R mutation) in tumor tissue was detected by non-squamous NSCLC, and EGFR mutation (ex19del or L858R mutation) in ctDNA before treatment;...
Trial ID:
Source:
Title:
Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC
Excerpt:
...- Epidermal Growth Factor Receptor(EGFR)mutations confirmed by molecular detection (including, but...
Trial ID:
Source:
Title:
A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer
Excerpt:
...EGFR、ALK、ROS1 mutation-negative；Patients with squamous cell carcinoma may...
Trial ID:
Source:
Title:
Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC
Excerpt:
...- 5.Documented evidence of tumor harboring an activating EGFR mutation (exon19 del and L858R)...
Trial ID:
Source:
Title:
EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC
Excerpt:
...- Centrally confirmed EGFR exon 19 deletion (del19) or exon 21 mutation (L858R)...
Trial ID:
Source:
Title:
Anlotinib Versus Docetaxel as the Second-line Treatment in EGFR Wild Type Patients With Advanced NSCLC
Excerpt:
...- Patients who has failed from the first-line Platinum-based Doublet chemotherapy harbouring epidermal growth factor receptor(EGFR) sensitive mutations negetive, confirmed by pathological or blood test results) ）,ALK/ROS1 mutation-negative or unknown (For recurrent patients, adjuvant chemotherapy, neoadjuvant chemotherapy or neoadjuvant chemotherapy plus adjuvant were assessed for eligibility, and the last treatment time must be more than 6 months before enrollment）...
Trial ID:
Source:
Title:
Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin
Excerpt:
...- EGFR mutations confirmed by molecular detection (including, but...
Trial ID:
Source:
Title:
Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC
Excerpt:
...- EGFRALKROS1 wildtype or unknown,or patients with EGFRALKROS1 mutations but refuse to receive corresponding inhibitors' treatment...
Trial ID:
Source:
Title:
Phase I Study of the Combination of Anlotinib With Gefitinib
Excerpt:
...- Epidermal Growth Factor Receptor(EGFR)mutations confirmed by molecular detection (including, but...
Trial ID:
Source:
Title:
Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel
Excerpt:
...- Patients with EGFR、ALK、ROS1 Mutation-negative were eligible....
Trial ID:
Less C2 evidence
Source:
Title:
Anlotinib plus chemotherapy for T790M-negative EGFR-mutant non-sqNSCLC resistant to TKIs: A multicenter phase 1b/2 trial
Published date:
11/08/2022
Excerpt:
The median PFS was 5.75 (95% confidence interval, 4.37-7.52) months. The objective response rate was 47.4% (95% confidence interval, 24.5%-71.1%)….Anlotinib plus platinum and pemetrexed showed promising antitumor activity with manageable toxicity in patients with T790M-negative EGFR-mutant advanced nonsquamous NSCLC after progression on first- or second-generation EGFR TKIs.
Secondary therapy:
Chemotherapy + pemetrexed
DOI:
10.1111/1759-7714.14713
Trial ID:
Source:
Title:
EP08.02-033 - Anlotinib in Elderly Patients With Advanced Non-squamous NSCLC Who Had Not Received Systemic Chemotherapy: A Single-Arm, Phase II Study
Published date:
07/12/2022
Excerpt:
In the phase II trial, Pts with non-squamous non-small cell lung cancer (NSCLC) aged 70 years or older who had not received systemic chemotherapy were included. Pts harboring EGFR or ALK mutations were enrolled after the failure of TKIs therapy….The median PFS was 4.8 months (95% CI: 2.6-8.4) and the median OS was not reached, The ORR was 6% (2/34), and the DCR was 85% (29/34).
Trial ID:
